Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Moderna, Inc.
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
May 6, 2026
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
May 1, 2026
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
April 21, 2026
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
April 21, 2026
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
April 21, 2026
Moderna to Present at Upcoming Conferences in May 2026
April 21, 2026
←
Previous Page
1
2
3